iTeos' Financial Health Underpins Clinical Advancements With $655 million in cash, iTeos Therapeutics has secured a runway through 2027. However, its R&D spending surged 28% in 2024, contributing to a $134.4 million net loss. The company remains focused on pivotal trials, including GALAXIES Lung-201, with results expected later this year.456